An approach to control relapse of inflammatory lesions after discontinuation of primary therapy.
Long-term treatment with the fungal metabolite drug FTY720 (Fingolimod) was shown to be highly effective in controlling viral immunopathological lesions. However, in this report we show that the anti-inflammatory effect of FTY720 in herpes simplex virus-1 (HSV-1) induced ocular inflammation is lost upon the discontinuation of treatment and lesions rapidly recurred. The lesions that developed after FTY720 treatment withdrawal involved mainly Th17 cells rather than Th1 cells explained in part by differential expression of surface CD103, an integrin that permits migration of effector cells to inflammatory sites. The expression of IL-6, a proinflammatory cytokine involved in the generation of Th17 cells, was found to be increased in FTY treated mice as compared to controls and this effect could be abrogated upon administration of neutralizing antibody to IL-6. Furthermore, IL-17RKO mice failed to show the recurrence of stromal keratitis (SK) lesions upon FTY720 withdrawal. These results indicate that approaches such as neutralization of proinflammatory cytokines might be considered along with FTY720 treatment if interruption of drug therapy becomes necessary.
Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America.
Pradeep B J
PB
Reddy
Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America.
Sharvan
S
Sehrawat
Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America.
Amol
A
Suryawanshi
Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America.
Naveen K
NK
Rajasagi
Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America.
Madhu
M
Khatri
Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, United States of America.
Barry T
BT
Rouse
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000494:pharmacology; D002454:Cell Differentiation; D004195:Disease Models, Animal; D005260:Female; D000068876:Fingolimod Hydrochloride; D018259:Herpesvirus 1, Human / Q000276:immunology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology; D015850:Interleukin-6 / Q000276:immunology; D016849:Keratitis, Herpetic / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control* / Q000821:virology; D051379:Mice; D018345:Mice, Knockout; D011409:Propylene Glycols / Q000008:administration & dosage / Q000494:pharmacology; D049349:Receptors, Lysosphingolipid / Q000378:metabolism; D012008:Recurrence; D055502:Secondary Prevention; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D000093242:Interleukin-6 Inhibitors
D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000068876:Fingolimod Hydrochloride; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D011409:Propylene Glycols; D049349:Receptors, Lysosphingolipid; D013110:Sphingosine; D000093242:Interleukin-6 Inhibitors